PFE Stock Price - Pfizer Inc. Stock Quote (U.S.: NYSE) - MarketWatch

Open $32.94
Day Range 32.9100 - 33.2500
52 Week Range 29.8300 - 37.3900
Market Cap $196.76B
Shares Outstanding 5.97B
Public Float 5.96B
Beta 0.81
Rev. per Employee $545.06K
P/E Ratio 28.03
EPS $1.19
Yield 3.85%
Dividend $0.32
Ex-Dividend Date May 10, 2017
Short Interest 45.71M 05/31/17
% of Float Shorted 0.77%
Average Volume 21.94M

5 Day	1.96%
1 Month	3.36%
3 Month	-3.01%
YTD	2.28%
1 Year	-4.40%

MarketWatch
Other Dow Jones

Opinion

Five reasons you have to buy biotech stocks now

Jun. 20, 2017 at 5:11 a.m. ET
by Michael Brush

Three must-own cancer stocks for your biotechnology portfolio

Jun. 19, 2017 at 5:37 p.m. ET
by Michael Brush

A major value fund mirrors a major growth one more than you may expect

Jun. 19, 2017 at 5:37 p.m. ET
by Ryan Vlastelica

Opioids are ravaging the U.S., but they’re still the best pain drug we’ve got

Jun. 19, 2017 at 1:18 p.m. ET
by Emma Court

Dow, S&P 500 close at records as tech stocks rebound

Jun. 13, 2017 at 4:38 p.m. ET
by Barbara Kollmeyer

Eli Lilly stock rises 1.5% after pain drug gets fast track designation from FDA

Eli Lilly & Co. shares rose 1.5% in premarket trade Tuesday after the company said its pain drug with Pfizer Inc. has received fast track designation from the Food and Drug Administration, which is intended to hasten the development and approval of drugs for serious conditions. Pfizer shares were up 0.2% premarket. The drug, tanezumab, got the designation for chronic pain in patients with osteoarthritis and chronic low back pain. Tanezumab is currently in late-stage development, and results from clinical trials are expected to start being released in 2018, the companies said. If approved, the drug could be a much-needed new tool for doctors amid a national opioid crisis. The drug is also being studied in patients with cancer pain. Eli Lilly shares have dropped 3.9% over the last three months, and Pfizer shares have dropped 4.1%, compared with a 2.4% rise in the S&P 500 .

Jun. 13, 2017 at 8:53 a.m. ET
by Emma Court

Eli Lilly stock rises 1% after pain drug gets fast track designation from FDA

Jun. 13, 2017 at 8:40 a.m. ET
by Emma Court

Weekend roundup: What Apple expects you to do | Millennials enter the stock market | Arguing over Tesla’s stock

Jun. 11, 2017 at 7:52 a.m. ET
by Philip van Doorn

Johnson & Johnson’s new prostate cancer advances could signal trouble for Pfizer

Jun. 8, 2017 at 7:46 a.m. ET
by Emma Court

Beyond tech: How other sectors are driving the stock market

Jun. 6, 2017 at 4:24 p.m. ET
by Jeff Reeves

The contrarian investor’s best bet is coming down the pike

May. 24, 2017 at 10:03 a.m. ET
by Michael Brush

Most Dow stocks are below their 50-day moving averages

As the Dow Jones Industrial Average slips Wednesday below its 50-day moving average (MA), which many technicians use to define the short-term trend, 17 of its 30 components are also below their respective 50-day MAs. Of that total, shares of Boeing Co. and Merck & Co. Inc. are below their 50-day MAs after closing above them on Tuesday, while UnitedHealth Group Inc.'s stock was above its 50-day MA as recently as Monday. Of that total, Pfizer Inc. , Chevron Corp. , General Electric Co. , Intel Corp. , Verizon Communications Inc. , International Business Machines Corp. , Merck and Procter & Gamble Co. were also below their respective 200-day MAs, which are viewed as dividing lines between longer-term uptrends and downtrends. Exxon Mobil Corp.'s stock was below its 200-day MA, but was still above its 50-day MA. The Dow was down 237 points at 20743, below the 50-day MA at 20,783, but well above the 200-day MA at 19,547.

May. 17, 2017 at 12:01 p.m. ET
by Tomi Kilgore

Nasdaq closes at record while S&P 500, Dow slip amid political uncertainty

May. 16, 2017 at 4:36 p.m. ET
by Victor Reklaitis

Stocks eke out gains as Nasdaq closes at record for second day

May. 2, 2017 at 4:30 p.m. ET
by Sara Sjolin

Pfizer revenue falls as drugs lose exclusivity

Pfizer Inc. Tuesday said revenue fell 2% in its latest quarter to $12.78 billion as some of the company's legacy drugs lost patent protection in various key markets, though executives also blamed one-time factors and voiced optimism about prospects for the year.

May. 2, 2017 at 2:58 p.m. ET
by MarketWatch.com

Here’s the ‘last remaining cheap asset’ as the Fed pumps up prices for everything else

May. 2, 2017 at 9:16 a.m. ET
by Victor Reklaitis

Pfizer revenue falls as drugs lose exclusivity

Pfizer Inc. Tuesday said revenue fell in its latest quarter as some legacy drugs lost market exclusivity. Shares of the company are down 1.1% in premarket trading. Pfizer said revenue in its essential health unit, which includes the antidepressant Pristiq and anti-epileptic drug Lyrica, fell 10% in the first quarter from a year earlier.

May. 2, 2017 at 7:54 a.m. ET
by MarketWatch.com

Pfizer reports Q1 profit beat, revenue miss

Pfizer Inc. reported a first-quarter profit beat and revenue miss early Tuesday. Earnings for the latest quarter rose to $3.12 billion, or 51 cents per share, from $3.04 billion, or 49 cents per share, in the year-earlier period. Adjusted earnings-per-share were 69 cents, compared with the FactSet consensus of 67 cents. Revenue rose to $12.78 billion from $13.01 billion, compared with the FactSet consensus of $13.09 billion. Pfizer said its latest results were affected by one less U.S. selling day and two fewer international selling days, compared to the year-earlier period. The latest results include some legacy operations from Hospira Infusion Systems, which Pfizer completed the sale of to ICU Medical in early February. Pfizer shares have surged 6.5% over the last three months, compared with a 4.7% rise in the S&P 500 .

May. 2, 2017 at 7:01 a.m. ET
by Emma Court

Pfizer stock rises 1% in pre-market trade

May. 2, 2017 at 6:52 a.m. ET
by Emma Court

Pfizer Q1 revenue $12.8 bln vs. $13.0 bln; FactSet consensus $13.1 bln

May. 2, 2017 at 6:51 a.m. ET
by Emma Court

Can AstraZeneca Thrive on Its Own? Big Test Looms

The drug maker hopes the results of a trial for Mystic, a lung-cancer treatment, will prove it was right to fend off a 2014 takeover offer and commit to developing immunotherapy medicines.

Jun. 19, 2017 at 8:00 a.m. ET
on The Wall Street Journal

JNJ Diabetes Data Benefit Lilly, Hurt Merck

Lilly’s Jardiance could gain the most from CANVAS, while Merck’s Januvia may face incremental pressure.

Jun. 14, 2017 at 11:12 a.m. ET
on Barron's Online

Stocks to Watch: Apple, Netflix, Amazon, Tesla, Nvidia

Among the companies with shares expected to trade actively in Tuesday’s session are Apple Inc. and the rest of the FAANG stocks, semiconductor companies led by Nvidia Corp. and Tesla Inc.

Jun. 13, 2017 at 9:28 a.m. ET
on The Wall Street Journal

Under Immelt, GE Was the Worst Performer in the Dow

General Electric shareholders endured a rough ride during Jeff Immelt's tenure atop the firm. The stock is down about 30% since he took the reins from legendary GE Chairman Jack Welch in 2001.

Jun. 12, 2017 at 12:54 p.m. ET
on The Wall Street Journal

U.S. Probe Sheds Light on Charities’ Role in Boosting Drug Sales

U.S. sales of blockbuster prostate-cancer drugs have dropped sharply since the start of a federal investigation into charities that help patients pay for these drugs, a sign of how much the pharmaceutical industry relies on these foundations to support revenue.

Jun. 11, 2017 at 9:24 p.m. ET
on The Wall Street Journal

NIH Plans Partnerships With Drug Companies to Tackle Opioid Abuse

The National Institutes of Health, responding to a national drug-overdose epidemic, said it will create partnerships with drug companies to speed research on treatments for opioid abuse and on pain drugs that don’t cause addiction.

May. 31, 2017 at 7:23 p.m. ET
on The Wall Street Journal

Tesaro Explores Sale

Tesaro is exploring a sale, according to people familiar with the matter, two months after the cancer-treatment developer won a key drug approval.

May. 31, 2017 at 3:57 p.m. ET
on The Wall Street Journal

Still 2007: Year Regains Perch Atop Deal-Making Chart

The year 2007 has reclaimed its title as the biggest for global deal-making. With $4.3 trillion in global deals, 2007 was unseated two years ago by 2015, which ended with $4.7 trillion in announced deals. But since then, many of those deals have unraveled.

May. 19, 2017 at 5:27 p.m. ET
on The Wall Street Journal

Charting the Market

A graphic look at selected stock activity for the week ended May 12, 2017. Included are Macy’s, PetMed Express, and Electronic Arts.

May. 13, 2017 at 12:23 a.m. ET
on Barron's Online

Tepper’s Appaloosa Trims Bets on Pharmaceuticals

David Tepper's Appaloosa Management trimmed its wagers on pharmaceutical companies in the first quarter and sold out of retailer J.C. Penney.

May. 12, 2017 at 5:19 p.m. ET
on The Wall Street Journal

Goldman’s Investment Bankers Follow Their Own Advice

Goldman Sachs is splitting its investment bankers who focus on healthcare and consumer and retail companies into two groups with separate leaders.

May. 12, 2017 at 12:07 p.m. ET
on The Wall Street Journal

Allergan Stock Can Inject Profits Into Your Portfolio

Best known for its wrinkle-erasing Botox injections, Allergan has a big drug pipeline and shares look cheap.

May. 10, 2017 at 7:16 a.m. ET
on Barron's Online

Novartis Has the Right Prescription for Profits

New branded and generic drugs could propel the Swiss pharma to a multiyear run of earnings gains.

May. 6, 2017 at 12:53 a.m. ET
on Barron's Online

Four Small Biotechs See Bullish April Stock Buys

Celgene bought more Agios. The Biotechnology Value Fund disclosed large positions in three firms.

May. 3, 2017 at 5:51 a.m. ET
on Barron's Online

Revolt Against Sky-High Drug Prices Prompts a Pioneer to Cash Out

Jeffrey Aronin hoped to eventually sell Marathon Pharmaceuticals for billions of dollars, but then the company said it would charge $89,000 a year for a muscular-dystrophy drug.

May. 2, 2017 at 11:59 p.m. ET
on The Wall Street Journal

U.S. Stocks Edge Higher on Mixed Corporate Earnings

U.S. stock indexes edged higher, as gains in shares of industrial companies offset losses in the energy sector.

May. 2, 2017 at 5:02 p.m. ET
on The Wall Street Journal

Pfizer Revenue Falls as Drugs Lose Exclusivity

Pfizer said revenue fell in its latest quarter as some legacy drugs lost market exclusivity.

May. 2, 2017 at 11:37 a.m. ET
on The Wall Street Journal

S&P 500 Pacing for Most Earnings and Sales ‘Beats’ in Over a Decade

The proportion of S&P 500 companies beating analysts' forecasts both on earnings and sales is pacing to be the best in 13 years.

May. 2, 2017 at 10:20 a.m. ET
on The Wall Street Journal

Stocks to Watch: Aetna, Pfizer, Apple

Among the companies with shares expected to trade actively in Tuesday's session are Aetna Inc., Pfizer Inc. and Apple Inc.

May. 2, 2017 at 9:18 a.m. ET
on The Wall Street Journal

S&P 500 Rises, Led by Tech Shares

A climb in technology shares helped push the S&P 500 higher and the Nasdaq Composite to a record.

May. 1, 2017 at 5:57 p.m. ET
on The Wall Street Journal

Other News
Press Releases

Regeneron’s Praluent May See Gradual Increase in 2017 Demand

In 1Q17, Regeneron (REGN) and Sanofi’s (SNY) Praluent reported global revenues close to $36.0 million, of which $25.0 million were earned from the US market.

Jun. 16, 2017 at 5:13 p.m. ET
on MarketRealist.com

Better Buy: Pfizer Inc. vs. AbbVie Inc.

Jun. 20, 2017 at 7:11 a.m. ET
on Motley Fool

Top Stock Reports for Chevron, Pfizer & Boeing

Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Pfizer (PFE), and Boeing (BA).

Jun. 19, 2017 at 5:06 p.m. ET
on Zacks.com

3 Biotech Stocks That More than Doubled Year to Date

Here is a look at Puma (PBYI) and two other biotech stocks that have recorded massive gains so far in 2017.

Jun. 19, 2017 at 8:53 a.m. ET
on Zacks.com

Why Exelixis, Inc. Zoomed Higher Today

Jun. 19, 2017 at 5:21 p.m. ET
on Motley Fool

FDA Grants Fast-Track Designation to Tanezumab

Tanezumab is an investigational drug co-developed by Eli Lilly (LLY) and Pfizer (PFE).

Jun. 16, 2017 at 7:00 a.m. ET
on MarketRealist.com

Regeneron Continues to Explore Eylea in Multiple New Indications

To further expand Eylea’s label, Regeneron is studying the drug in combination with angiopoietin2 (or Ang2) antibody nesvacumab in two Phase 2 trials.

Jun. 16, 2017 at 5:13 p.m. ET
on MarketRealist.com

Eylea Continues to Be a Key Growth Driver for Regeneron in 2017

In 1Q17, Regeneron's (REGN) Eylea reported revenues of about $854.0 million in the US market, which is a YoY (year-over-year) rise of about 9.0%.

Jun. 16, 2017 at 5:13 p.m. ET
on MarketRealist.com

Can AstraZeneca Thrive on Its Own? Big Test Looms

The drug maker hopes the results of a trial for Mystic, a lung-cancer treatment, will prove it was right to fend off a 2014 takeover offer and commit to developing immunotherapy medicines.

Jun. 19, 2017 at 8:00 a.m. ET
on The Wall Street Journal

How Eli Lilly’s Taltz Performed in Clinical Trials

On June 15, 2017, Eli Lilly announced data from a study that evaluated the safety and efficacy of Taltz in patients with active psoriatic arthritis.

Jun. 16, 2017 at 7:00 a.m. ET
on MarketRealist.com

Could Legalized Marijuana Be Making Big Pharma Nervous?

Jun. 18, 2017 at 2:03 p.m. ET
on Motley Fool

3 Dividend Stocks for Successful Investors

Jun. 17, 2017 at 11:42 a.m. ET
on Motley Fool

Dow 30 Stock Roundup: GE Appoints Flannery as CEO; UTX, CAT Hike Dividends

The Dow notched up successive record gains during a week marked by losses for tech stocks

Jun. 16, 2017 at 4:19 p.m. ET
on Zacks.com

Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused

Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.

Jun. 16, 2017 at 8:27 a.m. ET
on Zacks.com

Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs?

Clovis Oncology (CLVS) and Tesaro (TSRO) could each deliver blockbuster ovarian cancer drugs and grab takeover interest, an analyst said Friday ahead of a key trial for Clovis, expected later this month. The duo rivals bigger AstraZeneca (AZN), whose $87.3 billion market cap is more than eight times that of Clovis and Tesaro combined. Clovis and Tesaro joined AstraZeneca on the PARP-inhibitor market within the last year. PARP inhibitors work by

Jun. 16, 2017 at 1:29 p.m. ET
on Investors Business Daily

2 Incredibly Cheap Biotech Stocks

Jun. 16, 2017 at 12:47 p.m. ET
on Motley Fool

Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug

Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.

Jun. 15, 2017 at 9:08 a.m. ET
on Zacks.com

10 Stocks Ready for a BIG Move – In Either Direction

Jun. 15, 2017 at 3:25 p.m. ET
on InvestorPlace.com

Will These Cutting-Edge Cancer Killers Reignite The Biotech Rally?

The biotech industry, always a highly technical conundrum for investors, might currently pose an even greater challenge — and offer even greater risks — than usual. Early industry innovators like Amgen (AMGN), Biogen (BIIB) and Gilead Sciences (GILD) currently find themselves in "big trouble," according to Loncar Investments Chief Executive Brad Loncar, largely as victims of their own success. But cancer and rare disease specialists Kite Pharma

Jun. 15, 2017 at 11:42 a.m. ET
on Investors Business Daily

Acceleron (XLRN) Kidney Cancer Candidate Fails in Phase II

Acceleron Pharma Inc.'s (XLRN) announced disappointing results from a phase II study evaluating its pipeline candidate dalantercept in combination with Pfizer's (PFE) Inlyta (axitinib) for treatment of advanced renal cell carcinoma (RCC).

Jun. 14, 2017 at 3:25 p.m. ET
on Zacks.com

Corporate News Blog - Bristol-Myers Squibb Announces Sale of Swords Plant; Set to Expand its Biologics Portfolio

Jun. 19, 2017 at 8:24 a.m. ET
on ACCESSWIRE

Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine

Jun. 19, 2017 at 8:00 a.m. ET
on BusinessWire - BZX

Pfizer Announces Results from XELJANZ® (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress

Jun. 16, 2017 at 4:35 a.m. ET
on BusinessWire - BZX

Health Advance Announces New Management in Most Recent 10Q

Jun. 14, 2017 at 5:38 p.m. ET
on PR Newswire - PRF

Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients

Jun. 14, 2017 at 1:20 p.m. ET
on BusinessWire - BZX

Basilea announces license agreement with Pfizer for antifungal Cresemba(R) (isavuconazole) for Europe, Russia, Turkey and Israel

Jun. 14, 2017 at 1:15 p.m. ET
on Globe Newswire

Patented Biotechnology Formulations Resulting in New Generation of Animal Healthcare Medications and Treatments

Jun. 14, 2017 at 8:45 a.m. ET
on PR Newswire - PRF

Nearly One in Four New and Expectant Parents Have Never Heard of Invasive Pneumococcal Disease According to a New Survey

Jun. 13, 2017 at 9:00 a.m. ET
on BusinessWire - BZX

Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies

Jun. 10, 2017 at 1:00 p.m. ET
on BusinessWire - BZX

Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer

Jun. 9, 2017 at 8:00 a.m. ET
on BusinessWire - BZX

Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer

Jun. 9, 2017 at 8:00 a.m. ET
on PR Newswire - PRF

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Jun. 7, 2017 at 10:00 a.m. ET
on BusinessWire - BZX

Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency

Jun. 7, 2017 at 7:30 a.m. ET
on PR Newswire - PRF

Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin Cardiomyopathy

Jun. 6, 2017 at 8:00 a.m. ET
on BusinessWire - BZX

WBENC Sets the Stage in Las Vegas for the 2017 Student Entrepreneur Program and Pitch Competition

Jun. 5, 2017 at 11:00 a.m. ET
on PR Newswire - PRF

Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer

Jun. 3, 2017 at 4:30 p.m. ET
on BusinessWire - BZX

AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer

May. 31, 2017 at 4:05 p.m. ET
on BusinessWire - BZX

Pfizer Announces Acceptance of Regulatory Submissions by U.S. FDA and European Medicines Agencyfor SUTENT® (sunitinib) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery

Pfizer Announces Acceptance of Regulatory Submissions by U.S. FDA and European Medicines Agencyfor SUTENT® (sunitinib) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery

May. 31, 2017 at 8:30 a.m. ET
on BusinessWire - BZX

European Commission Approves Pfizer’s TRUMENBA® to Help Prevent Meningococcal Group B Disease in Adolescents and Adults

May. 30, 2017 at 10:00 a.m. ET
on BusinessWire - BZX

Blog Coverage: Pfizer Cautions Shareholders Against Accepting TRC Capital Corporation's Mini-Tender Offer

May. 26, 2017 at 8:23 a.m. ET
on ACCESSWIRE

Pfizer, Inc. is a research-based, global biopharmaceutical company, which engages in the manufacture of vaccines and injectable biologic medicines. It operates through the following business segments: Global Innovative Pharmaceutical, Global Vaccines, Oncology and Consumer Healthcare, and Global Established Pharmaceutical. The Global Innovative Pharmaceutical segment focuses on developing, registering and commercializing novel, value creating medicines that significantly improve patients lives. The Global Vaccines, Oncology and Consumer Healthcare segment engages in the development and commercialization of vaccines and products for oncology and consumer healthcare. The Global Established Pharmaceutical segment includes the brands that have lost market exclusivity and, generally, the mature, patent-protected products that are expected to lose exclusivity through 2015 in most major markets and, to a much smaller extent, generic pharmaceuticals. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 23 Full Ratings

5 Biggest Price Target Changes For Monday

Jun. 12, 2017 at 10:11 a.m. ET
on Benzinga.com

The Current State Of The Breast Cancer Treatment Space

May. 23, 2017 at 8:59 a.m. ET
on Benzinga.com

Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns

May. 16, 2017 at 11:16 a.m. ET
on Benzinga.com

Name	Chg %	Market Cap
Amgen Inc.	1.64%	$121.49B
AstraZeneca PLC ADR	0.29%	$86.29B
GlaxoSmithKline PLC ADR	-0.09%	$106.37B
Novartis AG ADR	0.75%	$210.04B
Abbott Laboratories	1.41%	$84.84B

Competitor Data Provided By

Asia Dow	3,343.85	3.29	0.10%
Nikkei 225	20,230.41	162.66	0.81%
Hang Seng	25,843.04	-81.51	-0.31%
Shanghai	3,140.01	-4.36	-0.14%
Sensex	31,297.53	-14.04	-0.04%
Singapore	3,230.42	-16.76	-0.52%

Pfizer Inc.

$ 33.05

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers

Eli Lilly stock rises 1% after pain drug gets fast track designation from FDA

Pfizer stock rises 1% in pre-market trade

Pfizer Q1 revenue $12.8 bln vs. $13.0 bln; FactSet consensus $13.1 bln

Stocks

Columns

Authors

Topics

^$ 33.05